Table 5.

Association of female menopausal hormone use with endometrial cancer among women age ≥40 years, stratified by obesity status, 1995–2013a

Non-obese (BMI < 30 kg/m2)Obese (BMI ≥ 30 kg/m2)
CasesRatebIRRc95% CICasesRatebIRRc95% CI
Estrogen-only FMH used
Estrogen + progestin FMH usef
  • aAnalysis restricted to women ≥40 years of age, not taking oral contraceptives, with known menopause status, and not reporting use of multiple FMH types.

  • bMultivariable model stratified by age and study period and adjusted for age at menarche, parity, menopausal status, oral contraceptive use, smoking, body mass index (continuous), and vigorous physical activity.

  • cCrude rate per 100,000 person-years.

  • dAdditionally adjusted for estrogen plus progestin FMH use.

  • eNever reported any FMH use.

  • fAdditionally adjusted for estrogen-only FMH use.